Epidermal growth factor receptor (EGFR) mutant NSCLC is a distinct biological entity that should be preferentially treated with an EGFR tyrosine kinase inhibitor (TKI) [2]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.